TAVR Performance Sustained In Long-Term Data
This article was originally published in The Gray Sheet
Executive Summary
Five-year follow-up data on Edwards’ Sapien and two-year data on Medtronic’s CoreValve presented at the TCT conference in Washington, D.C., show sustained efficacy and safety for transcatheter aortic valves in patients too ill for surgery.